The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-GRANOLAS heavier than the FAAAM'ous five

Tue, 28th Apr 2020 10:44

* European stocks inch higher

* STOXX 600 +1.3%, FTSE 100 +1.2%

* Germany's Wirecard plunges 20%

* HSBC, UBS, Santander: mixed Q1 results
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Thyagaraju Adinarayan
(thyagaraju.adinarayan@thomsonreuters.com), Joice Alves (joice.alves@thomsonreuters.com) and
Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

GRANOLAS HEAVIER THAN THE FAAAM'OUS FIVE (0935 GMT)

Major growth/defensive plays with solid balance sheets in Europe which are as sturdy as rock
are going to shape-up the pan-European STOXX 600's moves over the next few years as
they come out almost unscathed from this virus shock.

What matters is, who are these top guns?

Goldman dubs these companies as GRANOLAS -- Glaxosmithkline, Roche, ASML
, Nestle, Novartis, Novo Nordisk, L'Oreal, LVMH
, Astrazeneca, SAP, Sanofi.

"These (companies) have relatively strong balance sheets, low volatility growth and good
dividend yields, around 2%-2.5% (much higher than other asset classes)," Goldman writes in a
note.

They make up 24% of the STOXX 600, heavier than Facebook, Amazon, Apple, Alphabet and
Microsoft's weight on the S&P 500.

(Thyagaraju Adinarayan)

*****

BP: DIVIDEND PRIDE? (0812 GMT)

There's nothing to be happy about the first-quarter beat, investors reckon, as BP's
cash flow is drying up fast and the British oil major is still not in a mood to give up payouts
to shareholders.

Let's not forget, second-quarter results are poised to be far worse given how oil prices
have crushed to levels not seen for decades. Citi and Credit Suisse warn about weakening cash
flows and the reflection of it in the company's balance sheet.

"Yet the decision to pay a full dividend in a quarter when cash flow is weakening, net debt
shot up by $6B and the outlook for 2Q is poor can hardly be called prudent," Citi says.

"If this is a short-sharp event of a few months then, with hindsight, BP's actions today can
be borne out. But does anyone really have enough clarity?"

(Thyagaraju Adinarayan)

*****

OPENING SNAPSHOT: A WIRECARD SENSATION BUT NO Q1 DRAMA (0748 GMT)

There were a lot of blue chips reporting much awaited trading updates this morning but it's
Wirecard the biggest mover on the STOXX 600 with a 20% fall after publishing a KPMG report into
its account.

The second top mover also comes from Germany but this one is in positive territory:
Lufthansa was up 10% after a report the government agreed a rescue package worth about 9 billion
euros.

Looking into the blue chips of the STOXX 50, there were 2 clear winners in today's batch of
Q1 earnings and both of them from Switzerland: UBS and ABB which were up over 4% each.

BP, on the other hand, retreated 1.9% which considering the unprecedented crash of oil
prices isn't a bad performance in the grand scheme of things.

All in all, this latest update on the state of Europe Inc. is no game changer but another
reminder of the pain to come.

Overall the trend is slightly more positive than it was in premarket. The broadly flat start
is morphing into a modest rise with the STOXX 600 up 0.4%.

U.S. futures are also slightly up.

(Julien Ponthus)

****

PLEASE SHELL OUT, INCOME SEEKERS PRAY (0718 GMT)

With UK blue-chip BP agreeing to maintain its 10.5 pence-per share dividend, it's a
consolation to British income funds which last month saw over 15 billion pounds ($18.6 billion)
in payouts cancelled or suspended.

April has been better with some 5.6 billion pounds in dividends being retained, stockbroker
AJ Bell highlights, and the BP news will add to the relief.

This week is a big one for income seekers with some 8.4 billion pound in dividends up for
grabs and statements from the top 5 payers -- Shell, BP, BAT and GlaxoSmithKline and HSBC, which
together accounted for over 40% of FTSE 100 payments last year.

HSBC had already bowed to regulators' pressure to hold back payouts and AJ Bell reckons
payouts from GSK and BAT are in the bag. That left Shell, which hasn't missed a dividend since
World War II, and BP, which last cancelled in 2010 after its Gulf of Mexico oil rig disaster.

Crude's 70% year-to-date fall means energy firms, from U.S. Occidental Petroleum to Norway's
Equinor, slash dividends. Yet, BP has come through so fund managers will be keeping their
fingers crossed for Shell tomorrow.

(Sujata Rao)

*****

ON THE Q1 RADAR: THE GOOD, THE BAD AND THE UGLY (0745 GMT)

It's not all black and white in terms of earnings this morning: good, bad and ugly reports
are painting a dark grey picture of Europe Inc in the time of coronavirus.

Under the spotlight this morning is of course the banking sector, the worst sectoral
performer since the novel coronavirus broke out earlier this year.

The world's largest wealth manager UBS had some good news to report with a 40% increase in
first-quarter net profit as clients increased trading activity during market turmoil.

But warnings that the upcoming coronavirus-induced recession will be ugly were given by
Spain's Santander and HSBC as both set aside more money for bad loans and recorded a fall in
profits.

Talking about profit declines, BP's net income fell by two-thirds as the pandemic
coronavirus hit oil demand. There's a lot at stake for investors as Shell and BP represent an
estimated 24% of the £75bn of FTSE 100 dividends for 2019 not yet hit by the market turmoil.

Interesting lesson about how M&A deals are sailing through the storm with BP amending the
financial terms of the $5.6 billion sale of its Alaska business.

Things got more ugly for Brazil's Embraer has begun an arbitration process against Boeing
after the U.S. planemaker abruptly cancelled a $4.2 billion deal over the weekend.

The assumption that pharmaceuticals are one of the safest bets in times like these was
comforted by Swiss drugmaker Novartis which beat expectations and confirmed its 2020 targets as
the pandemic prompted patients to stock up on their prescriptions in advance.

Another winning trend was illustrated by German online takeaway food company Delivery Hero
whose orders and revenues almost doubled as lockdowns closed restaurants and prompted more
people to order meals and groceries from home.

Rovio Entertainment, the maker of the 10-year-old "Angry Birds" mobile game series, said it
saw an increase in the number of downloads as well as user engagement.

Of course, a lot of the Q1 reports are just simply bad: guidance ditched, outlook grim,
dividend cut.

ABB said it expected the coronavirus epidemic to trigger a "sharp drop" in demand over the
next three months while Norway's Telenor warned that 2020 revenue and earnings will fall short
of its outlook.

Travis Perkins, Britain's largest distributor of building materials, said its total revenue
in the first three weeks of April was about one third of the same period in 2019 due to the
coronavirus crisis.

In terms of individual movers, Wirecard was down about 2% in early trading after it
published an investigation by KPMG into its account.

Also, it seems the suspense isn't over for Lufthansa as company and government sources
report that a state aid deal has not yet been secured.

(Julien Ponthus)

*****

MORNING CALL: UNCERTAIN OPEN WITH OIL UNDER PRESSURE (0535 GMT)

Futures are trading just marginally in the black this morning while another dive in oil
prices overnight put global markets under pressure.

Asian shares seemed set to end their session in the red but just managed to stage a comeback
into positive territory.

In Europe, it's another big earnings day across countries and sectors with the likes of
Banco Santander, Telenor and Novartis reporting Q1.

The earnings galore is expected to shed some light of how bad the last weeks of the quarter
really were and how ugly Q2 and Q3 look like at the moment.

(Julien Ponthus)

*****

(Reporting by Thyagaraju Adinarayan, Joice Alves, Julien Ponthus in London and Stafano Rebaudo
in Milan)

More News
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.